Ursodeoxycholic acid: paradigmatic transformation of the prevention of drug-induced liver lesions in clinical practice

Урсодезоксихолевая кислота: парадигмальная трансформация профилактики лекарственно индуцированных поражений печени в клинической практике
Maksim Potjagenko 1, Anna Nevoit 1, Oksana Kitura 1
More Detail
1 Educational and Scientific Institute of Postdegree Education of the Highest State Educational Establishment of Ukraine «Ukrainian Medical Stomatological Academy», Department of Internal Diseases and Medicine of Medical Emergencies with Skin and Venereal Diseases, Poltava, Ukraine
J CLIN MED KAZ, Volume 1, Issue 43, pp. 6-10. https://doi.org/10.23950/1812-2892-JCMK-00426
OPEN ACCESS 3428 Views 2519 Downloads
Download Full Text (PDF)

ABSTRACT

In the article argued the necessity of using tactics “hepatoprotektor’s escort” in clinical practice. In it demonstrates data about new effects of Ursodeoxycholic Acid and the capabilities of its application as a universal hepatoprotector have been elucidated. Inclusion of Ursodeoxycholic Acid in the combined therapy enhances the effectiveness of treatment of patients in many branches of medicine.
Keywords: Ursodeoxycholic Acid, drug-induced liver lesions

CITATION

Potjagenko M, Nevoit A, Kitura O. Ursodeoxycholic acid: paradigmatic transformation of the prevention of drug-induced liver lesions in clinical practice. Journal of Clinical Medicine of Kazakhstan. 2017;1(43):6-10. https://doi.org/10.23950/1812-2892-JCMK-00426

REFERENCES

  • Zhuravleva L.V., Kryvonosova E.M., Lopyna N.A. Use of Ursodeoxycholic Acid in Internal Medicine. Praktykuiuchyi likar. 2014; 4:25-32.
  • Potjagenko M.M., Nevoit A.V., Service hepatoprotective therapy by Ursodeoxycholic Acid. Health of Ukraine. 2007; 18: 69-71.
  • Potjagenko M.M., Nevoit A.V., Kitura О.Е. Pleiotropic effects of ursodeoxycholic acid are an additional argument for expansion of clinical application. Suchasna gastroenterologіya. 2017; 1:69-71.
  • Aagaard K, Petrosino J, Keitel W, Watson M, Katancik J, Garcia N, Patel S, Cutting M, Madden T, Hamilton H, Harris E. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. The FASEB Journal. 2013; 1;27(3):1012-22. http://www.fasebj.org/content/27/3/1012
  • Ridlon JM, Bajaj JS. The human gut sterolbiome: bile acid-microbiome endocrine aspects and therapeutics. Acta Pharmaceutica Sinica B. 2015; 31;5(2):99-105.
  • Thiessen K. Die Wirkung von Ursodeoxycholsäure auf die Cholesterin-und Gallensäurebiosynthese (Doctoral dissertation, lmu).
  • Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. Journal of hepatology. 2001; 1;35(1):134-46.
  • Paumgartner G. Importance of bile acids in the pathogenesis and therapy of hepatic diseases. Cholestatic Liver Disease, 2004; 111 p.
  • Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002; 1;36(3):525-31.
  • Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000; 1;32(6):1196-9.
  • Abdelkader NF, Safar MM, Salem HA. Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson’s disease: modulation of mitochondrial perturbations. Molecular neurobiology. 2016; 1;53(2):810-7.
  • Maksymova E.V., Kliarytskaia Y.L. Hepatoxicity at patients of a rheumatic profile: features of a current, possibility of correction. Krumskyi terapevtycheskyi zhurnal. 2015; 1(24):58-64.
  • Moon SJ, Jeong JH, Jhun JY, Yang EJ, Min JK, Choi JY, Cho ML. Ursodeoxycholic acid ameliorates pain severity and cartilage degeneration in monosodium iodoacetate-induced osteoarthritis in rats. Immune network. 2014; 1;14(1):45-53.
  • Dubreuil M, Ruiz‐Gaspà S, Guañabens N, Peris P, Álvarez L, Monegal A, Combalia A, Parés A. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver international. 2013; 1;33(7):1029-38. doi: 10.1111/liv.12153. [Epub ahead of print] 
  • Otte C.M., Rothuizen J., Favier R.P et al. A morphological and immunohistochemical study of the effects of prednisolone or ursodeoxycholic acid on liver histology in feline lymphocytic cholangitis. J. Feline Med. Surg. 2014; 16(10):796-804.
  • Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, Nihtinen A, Hägglund H, Ringdén O, for Blood NG. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biology of Blood and Marrow Transplantation. 2014; 31;20(1):135-8. doi: 10.1016/j.bbmt.2013.10.014. [Epub ahead of print]
  • Troisi G, Crisciotti F, Gianturco V, D’Ottavio E, Lo IC, Formosa V, Bernardini S, Bellomo A, Marigliano B, Marigliano V. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study. La Clinica terapeutica. 2012;164(3):203-7.
  • Mortiboys H, Furmston R, Bronstad G, Aasly J, Elliott C, Bandmann O. UDCA exerts beneficial effect on mitochondrial dysfunction in LRRK2G2019S carriers and in vivo. Neurology. 2015; 8;85(10):846-52.
  • Cortez LM, Campeau J, Norman G, Kalayil M, Van der Merwe J, McKenzie D, Sim VL. Bile acids reduce prion conversion, reduce neuronal loss, and prolong male survival in models of prion disease. Journal of virology. 2015; 1;89(15):7660-72.
  • Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PloS one. 2014; 13;9(11):e112731.
  • De A.K., Sana S., Datta S. et al. Protective efficacy of ursodeoxycholic acid nanoparticles in animal model of inflammatory bowel disease. Microencapsul. 2014; 31(8):370-725.
  • Belonovskaya E.B., Naruta E. E., Lukivskaya O.YA. et al. Profilakticheskoe primenenie novyh proizvodnyh ursodeoksiholevoj kisloty (UDHC) pri ehksperimental’nom alkogol’nom steatogepatit. Zhurnal ehksperimental’noj i klinicheskoj farmakologii. 2013; 1:25-29.
  • Vang S., Longley K., Steer C.J., Low W.C. The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases. Glob. Adv. Health Med. 2014; 3(3):58-69.
  • Weingarden A.R.,Chen C., Zhang N. Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated with the Infection. J. Clin. Gastroenterol. 2016; 50 (8):30 – 624.
  • Wieser V., Gerner R., Moschen A.R., Tilq H. Liver complications in inflammatory bowel diseases. Diq D.K. 2013; 3(2):233- 238.